In a landmark ruling, the US Supreme Court upheld the individual insurance mandate at the heart of the Affordable CAre Act, which was the centerpiece of healthcare reform. For drugmakers and biotechs, the outcome means a degree of predictability, even though they will face billions of dollars in price cuts and fees.